Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2- Metastatic Breast Cancer in Postmenopausal Women in the USA.
Prajakta P MasurkarHaluk DamgaciogluAshish A DeshmukhMeghana V TrivediPublished in: PharmacoEconomics (2023)
At a willingness to pay of $100,000/QALY gained, our model predicts that combining CDK4/6 inhibitors plus letrozole is not cost effective with a marginal increase in QALYs at a high cost. Lowering the cost of these drugs or identifying patients who can receive maximal benefit from CDK4/6 inhibitors would improve the value of this regimen in patients.
Keyphrases
- postmenopausal women
- metastatic breast cancer
- cell cycle
- bone mineral density
- end stage renal disease
- newly diagnosed
- ejection fraction
- prognostic factors
- peritoneal dialysis
- type diabetes
- cell proliferation
- resistance training
- body composition
- adipose tissue
- insulin resistance
- drug induced
- high intensity
- patient reported